

Remarks/Arguments

By the present amendment, applicants have cancelled Claims 14 and 15. Therefore the claims remaining for consideration by the Examiner are Claims 8, 9, 11, 12, and 16-21. According to the Examiner, Claims 8, 9, 11, 12, and 16-21 are allowed.


The Examiner has rejected Claims 14 and 15 under 35 U.S.C. 103(a) as being unpatentable over Villani (4,659,716) in view of Hansen (5,658,899) and/or Strupczewski (4,954,503) and/or Congy (5,290,951).

In response, applicants have cancelled Claims 14 and 15.

It is requested that the Examiner enter the above amendment, and pass the case to issue.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7945



John D. Thallemer
Attorney for Applicants
Reg. No. 34,940

Date: March 28, 2005